Welcome to our dedicated page for Catheter Precision SEC filings (Ticker: VTAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Catheter Precision, Inc. (VTAK) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10‑K, 10‑Q and 8‑K, along with proxy statements and registration statements. As a NYSE American–listed medical device company focused on the cardiac electrophysiology market, Catheter Precision uses these filings to report on its business, financial condition, capital structure, and material events affecting VTAK stock.
Through its periodic reports, such as the annual Form 10‑K and quarterly Forms 10‑Q, Catheter Precision presents audited and interim financial statements, management’s discussion and analysis, and detailed risk factor sections. These documents expand on topics referenced in press releases, including the company’s history of operating losses, its need for additional financing to continue as a going concern, regulatory dependencies for its VIVO and LockeT products, and competitive and operational risks.
Current reports on Form 8‑K capture specific developments, such as reverse stock split implementation, amendments to short‑term promissory notes held by related parties, termination of an at‑the‑market equity offering program, and the release of quarterly financial results. Other 8‑K filings incorporate legal opinions related to registration statements and announcements about regulatory approvals in certain markets.
Definitive proxy statements on Schedule 14A outline matters submitted to stockholders, including proposals to authorize reverse stock splits, increase authorized shares, approve share issuances under NYSE American rules, and ratify the appointment of independent registered public accounting firms. These documents also describe the mechanics of virtual stockholder meetings and voting procedures.
On Stock Titan, AI-powered tools summarize lengthy filings so readers can quickly understand key points from Catheter Precision’s 10‑K, 10‑Q, and 8‑K reports without reading every page. Real-time updates from EDGAR ensure new filings appear promptly, while specialized views highlight items relevant to equity structure changes, financing arrangements, and governance decisions. Users can also review insider-related information disclosed in filings, such as amendments to notes held by executives and affiliated entities, to better understand relationships between management and the company’s capital structure.
Catheter Precision, Inc. reported that a group of investment funds and related managers collectively hold a significant passive stake in its common stock. The largest reported holder, Jonathan Juchno, beneficially owns 205,591 shares, representing 9.6% of the outstanding common stock. Other reporting persons include C/M Capital Master Fund, WVP Emerging Manager Onshore Fund, C/M Capital Partners, Mercer Street Global Opportunity Fund, Mercer Street Capital Partners, and Thomas Walsh, with individual stakes ranging from 2.6% to 6.4%. The ownership percentages are based on 2,131,563 shares of common stock outstanding as of the reference date. The filers certify that the securities were acquired and are held without the purpose or effect of changing or influencing control of Catheter Precision.
Catheter Precision, Inc. entered into Series J Exchange Agreements to swap accrued royalty rights with CEO David Jenkins and FatBoy Capital, LP into 9,489.488 shares of new Series J Convertible Preferred Stock, representing royalty amounts with a net present value of
The Series J Preferred Stock has a stated value of
The royalty rights and accrued royalty amounts are terminated as of December 31, 2025, removing this obligation. Separately, the company highlighted a strategic institutional financing for up to
Catheter Precision, Inc. (VTAK) received a Schedule 13G filing from investor Gregory Castaldo reporting a significant passive ownership stake in its common stock. Castaldo reports beneficial ownership of 176,674 shares of common stock, representing 7.5% of the outstanding shares.
The ownership percentage is calculated based on 2,357,127 shares of Catheter Precision common stock outstanding as verified with the company on February 11, 2026. Castaldo reports sole voting and dispositive power over all 176,674 shares and certifies that the shares are not held for the purpose of changing or influencing control of the company.
Catheter Precision, Inc. investor Joseph Reda filed a Schedule 13G reporting a significant ownership position in the company’s common stock. He beneficially owns 176,674 shares, representing 7.5% of the outstanding common stock, with sole voting and dispositive power over all these shares.
The 7.5% figure is based on 2,357,127 Catheter Precision common shares outstanding as verified with the issuer on February 11, 2026. Reda certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Catheter Precision.
Catheter Precision, Inc. entered into a complex private placement financing involving common stock and multiple new series of convertible preferred stock to raise capital and restructure its balance sheet. The initial closing covers 392,608 common shares at $1.43 each and 1,616.33 shares of Series C-1 preferred, initially convertible into up to 1,130,301 common shares, for total gross proceeds of
Investors also committed to additional Series C-2 and C-3 preferred purchases and obtained an option to buy up to
Separately, the company agreed to acquire 19.98% of Fly Flyte, Inc. from SEG Jets LLC in exchange for 5,250 shares of Series D preferred, valuing the stake at
Catheter Precision, Inc. Chairman and CEO David A. Jenkins reported derivative holdings in Series M Common Stock Purchase Warrants. On December 31, 2025, he reported 170,000 Series M warrants at an exercise price of $1.56 per underlying common share held directly, and another 170,000 Series M warrants at the same exercise price held indirectly.
The warrants are initially exercisable any time on or after the stockholder approval date, and each warrant terminates on the five and one half year anniversary of its initial exercise date. The indirect position is associated with FatBoy Capital LP, whose general partner is SeaCap Management LLC, where Mr. Jenkins serves as managing member.
Catheter Precision, Inc. extended the maturities of several 8% Short Term Promissory Notes held by entities associated with its executive chair and CEO, David A. Jenkins. On December 31, 2025, the company entered into Second Amendments to these notes, moving their maturity dates from January 31, 2026 to January 31, 2028 for a $500,000 note held by Jenkins Family Charitable Institute and to January 31, 2029 for notes with principal amounts of $500,000, $150,000, $250,000 and $100,000 held by Mr. Jenkins and FatBoy Capital, L.P.
The filing highlights that Mr. Jenkins is the managing member of the general partner of FatBoy Capital and the settlor of the Jenkins Family Charitable Institute, and that he and his affiliates also hold stock options and rights to receive 11.77% royalties on net sales of the LockeT device. The amendments are treated as a material definitive agreement and a direct financial obligation for the company.
Catheter Precision, Inc. director James J. Caruso reported a small equity transaction in the company’s stock. On 12/05/2025, he acquired 41 shares of common stock at a price of $0 per share in a transaction coded “C,” indicating a conversion. Following this transaction, he directly beneficially owned 50 shares of common stock.
The filing also shows activity in Series X Convertible Preferred Stock, with a conversion price of $0. On the same date, 7.932 shares of this preferred stock were involved in a transaction coded “C,” with no common shares shown as underlying afterward and 0 derivative securities beneficially owned. The accompanying note explains that the Series X Convertible Preferred Stock has no expiration date.
Catheter Precision, Inc. reported an insider stock transaction by its Chairman and CEO, David A. Jenkins. On 12/05/2025, Jenkins converted shares of Series X Convertible Preferred Stock into common stock at a stated price of $0 per share. Following these conversions, he directly held 13,799 common shares, with an additional 34,579 shares held indirectly through a partnership and 109 shares held indirectly through a charitable remainder unitrust. The filing notes that the preferred stock has no expiration date and that some of the indirectly held shares are controlled via entities managed by Jenkins or his spouse, clarifying the structure of his beneficial ownership.
Catheter Precision, Inc. reported that it has given notice to terminate its At-Market-Offering Agreement with Ladenburg Thalmann & Co. Inc., which supported its at-the-market equity offering program. The termination is scheduled to be effective on November 24, 2025.
The program allowed the company to offer and sell shares of common stock with an aggregate offering price of up to $4.3 million. Before issuing the termination notice, Catheter Precision sold approximately $4.0 million of common stock under this program, and it will not owe any termination penalties.
FAQ
What is the current stock price of Catheter Precision (VTAK)?
What is the market cap of Catheter Precision (VTAK)?
